Physician profile
Chad E Raymond
NPI 1437323912
$5,108.36
in general payments reported to CMS, 2019-2025
27 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $569 · 2021: $520 · 2022: $607 · 2023: $669 · 2024: $995 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,206.28 | 2019-2025 | |
| Amgen INC. | $915.91 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $329.75 | 2019-2024 | |
| Boston Scientific Corporation | $310.36 | 2020-2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $301.12 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $286.78 | 2019-2024 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.71 | 2019-2025 | Jardiance |
| Abbott Laboratories | $258.06 | 2019-2023 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $152.53 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $144.60 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $123.91 | 2020-2025 | Nexletol |
| Abiomed | $122.13 | 2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.09 | 2019-2025 | Lifevest |
| Bridgebio Pharma, INC. | $99.72 | 2025 | Attruby |
| Scpharmaceuticals INC. | $92.02 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.93 | 2021 | |
| Atricure, INC. | $56.38 | 2023-2025 | Synergy Ablation System |
| Lexicon Pharmaceuticals, INC. | $50.25 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $48.43 | 2019-2022 | |
| Irhythm Technologies, INC. | $34.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.59 | 2022-2023 | |
| Medtronic, INC. | $25.33 | 2024 | Corevalve Evolut R |
| Daiichi Sankyo INC. | $20.40 | 2023 | Injectafer |
| Kestra Medical Technology Services, INC. | $17.72 | 2025 | Assure Wcd |
| Shire North American Group INC | $16.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.03 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.